American Society of Hirudotherapy

LCI (Leech Carboxypeptidase Inhibitor)

Inhibitor of TAFI (thrombin-activatable fibrinolysis inhibitor) — synergizes with hirudin's anticoagulant action.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • LCI (Leech Carboxypeptidase Inhibitor)7.3 kDa
Molecular weight (kilodaltons) of LCI (Leech Carboxypeptidase Inhibitor) (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

LCI's in vitro TAFI inhibition does not establish clinical efficacy. No FDA-approved derivative exists. Mechanism is preclinical/biochemical only.

Ribbon model: human carboxypeptidase A2 in green with the small leech carboxypeptidase inhibitor (LCI) in orange bound at the entrance to its active site; a zinc ion (grey sphere) and a glutamic acid (ball-and-stick) sit in the active site.
Leech carboxypeptidase inhibitor (LCI) from Hirudo medicinalis in complex with human carboxypeptidase A2 (PDB 1DTD, X-ray diffraction). Source: PDBe, EMBL-EBI — PDB 1DTD · PDBe public data (public domain)

Molecular Profile

Category
Proteinase Inhibitor
Evidence tier
Preclinical
Molecular weight
7,300 Da
Source species
Hirudo medicinalis
Discovered
1998 · Reverter et al.
PDB structures
1ZLH

Biological Targets

  • → TAFI (carboxypeptidase B)

Key Citations

  1. Reverter D, Vendrell J, Canals F, Horstmann J, Aviles FX, Fritz H, Sommerhoff CP (1998), J Biol Chem · PMID 9830043
  2. Reverter D, Fernandez-Catalan C, Baumgartner R, Pfander R, Huber R, Bode W, Vendrell J, Holak TA, Aviles FX (2000), Nat Struct Biol · PMID 10742178

External Resources

Related Proteinase Inhibitor Compounds

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.